Technique Enables Efficient Gene Splicing In Human Embryonic Stem Cells Aug 15, 2009
The research was conducted in collaboration with Sangamo BioSciences, Inc., which designed and produced the zinc finger nucleases. The National Institutes of Health (NIH) and the Life Sciences Research Foundation provided funding for this research. (Science Daily)
Breakthrough In Transgenic Animal Production Enables Development Of New Human Disease Models Jul 25, 2009
ScienceDaily (July 24, 2009) Scientists from The Medical College of Wisconsin in Milwaukee, Sangamo Biosciences, Inc., Sigma-Aldrich Corporation, Open Monoclonal Technology, Inc. and INSERM have announced the creation of the first genetically modified mammals developed using zinc finger nuclease (ZFN) technology. See also. (Science Daily)
Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech Jun 29, 2009
June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: ) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines with novel characteristics for pharmaceutical protein production purposes using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology ... Sangamo BioSciences, Inc. is focused on researching and developing... (PR Newswire)
New technology builds better biotech crop May 21, 2009
In June 2008, Dow AgroSciences exercised their commercial option for exclusive property rights to Sangamo BioSciences Zinc-Finger Technology in plants. From there Dow AgroSciences continued to work on and develop this technology, said Sobek. (Minnesota Farm Guide, MN)
> The Pitch: CVAC puts pressure on physical disorders Mar 19, 2009
LIKELY COMPETITORS: Sangamo BioSciences Inc. on diabetic nerve damage treatment and Sirtris Pharmaceuticals Inc., owned by GlaxoSmithKline, on age-related diseases. PROFIT, REVENUE: The company is not now profitable but has about $17,000 in self-pay revenue that its leaders say is symbolic proof that people will pay to use the simulator. (San Jose Business Journal, CA)
